Literature DB >> 8586987

Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study.

E J Kasarskis1, L Tandon, M A Lovell, W D Ehmann.   

Abstract

We measured aluminum (Al), calcium (Ca), and iron (Fe) levels in neuronal cytoplasm and nucleus, capillaries, and neuropil in samples of ventral cervical spinal cord from 5 patients with sporadic amyotrophic lateral sclerosis (ALS) and 5 age-matched controls using laser microprobe mass spectrometry (LMMS). The concentration of Al was not altered in any area in the ALS samples. In contrast, Fe and Ca were increased 1.5-2-fold in the nucleus and cytoplasm of ALS neurons but not in capillaries and neuropil. These findings do not support the hypothesis that Al is enriched in spinal cord of sporadic ALS as has been reported for Guamanian ALS/Parkinson's dementia. The elevations of Fe in spinal neurons are consistent with reports of increased Fe in bulk samples of ALS spinal cord. The presence of increased Fe within spinal neurons may be significant in the pathogenesis of motor neuron degeneration by catalyzing the generation of reactive oxygen species within specific cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8586987     DOI: 10.1016/0022-510x(95)00037-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  41 in total

1.  Amyotrophic lateral sclerosis, enteral nutrition and the risk of iron overload.

Authors:  Alessio Molfino; Irma Kushta; Valentina Tommasi; Filippo Rossi Fanelli; Maurizio Muscaritoli
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

Review 2.  Mitochondrial metals as a potential therapeutic target in neurodegeneration.

Authors:  A Grubman; A R White; J R Liddell
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 3.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

4.  Implementation of X-ray fluorescence microscopy for investigation of elemental abnormalities in amyotrophic lateral sclerosis.

Authors:  B Tomik; J Chwiej; M Szczerbowska-Boruchowska; M Lankosz; S Wójcik; D Adamek; G Falkenberg; S Bohic; A Simionovici; Z Stegowski; A Szczudlik
Journal:  Neurochem Res       Date:  2006-05-03       Impact factor: 3.996

5.  Serum ferritin is a candidate biomarker of disease aggravation in amyotrophic lateral sclerosis.

Authors:  Jixu Yu; Nian Wang; Faying Qi; Xianjun Wang; Qiyi Zhu; Yucheng Lu; Huiling Zhang; Fengyuan Che; Wei Li
Journal:  Biomed Rep       Date:  2018-08-02

6.  Superoxide dismutase 1 modulates expression of transferrin receptor.

Authors:  Ruth Danzeisen; Tilmann Achsel; Ulrich Bederke; Mauro Cozzolino; Claudia Crosio; Alberto Ferri; Malte Frenzel; Edith Butler Gralla; Lea Huber; Albert Ludolph; Monica Nencini; Giuseppe Rotilio; Joan Selverstone Valentine; Maria Teresa Carrì
Journal:  J Biol Inorg Chem       Date:  2006-04-26       Impact factor: 3.358

7.  A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice.

Authors:  Sagit Golko-Perez; Tamar Amit; Orit Bar-Am; Moussa B H Youdim; Orly Weinreb
Journal:  Neurotox Res       Date:  2016-11-08       Impact factor: 3.911

8.  Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients.

Authors:  E F Goodall; M S Haque; K E Morrison
Journal:  J Neurol       Date:  2008-07-18       Impact factor: 4.849

Review 9.  Metal ion physiopathology in neurodegenerative disorders.

Authors:  Silvia Bolognin; Luigi Messori; Paolo Zatta
Journal:  Neuromolecular Med       Date:  2009-11-28       Impact factor: 3.843

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.